Alterity Therapeutics Crescita futura

Future criteri di controllo 2/6

Si prevede che gli utili di Alterity Therapeutics diminuiranno del 2.7% all'anno, mentre si prevede che il fatturato annuo crescerà del 25% all'anno.

Informazioni chiave

-2.7%

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Biotechs crescita degli utili	36.5%
Tasso di crescita dei ricavi	25.0%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	29 Aug 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

DB:PBN - Stime future degli analisti e dati finanziari passati (AUD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2026	7	-20	N/A	-20	1
6/30/2025	9	-18	-8	-18	1
6/30/2024	4	-19	-13	-13	N/A
3/31/2024	4	-16	-14	-14	N/A
12/31/2023	3	-12	-15	-15	N/A
9/30/2023	4	-13	-17	-17	N/A
6/30/2023	4	-14	-20	-20	N/A
3/31/2023	5	-14	-17	-17	N/A
12/31/2022	5	-14	-14	-14	N/A
9/30/2022	5	-14	-13	-13	N/A
6/30/2022	5	-13	-12	-12	N/A
3/31/2022	5	-13	-16	-16	N/A
12/31/2021	5	-13	-19	-19	N/A
9/30/2021	5	-14	-18	-18	N/A
6/30/2021	4	-15	-17	-17	N/A
3/31/2021	2	-16	-16	-16	N/A
12/31/2020	0	-16	-14	-14	N/A
9/30/2020	0	-15	-12	-12	N/A
6/30/2020	N/A	-13	-9	-9	N/A
3/31/2020	2	-13	-9	-9	N/A
12/31/2019	4	-13	-9	-9	N/A
9/30/2019	5	-12	-12	-12	N/A
6/30/2019	5	-12	-14	-14	N/A
3/31/2019	5	-11	-13	-13	N/A
12/31/2018	4	-10	-12	-12	N/A
9/30/2018	4	-9	-9	-9	N/A
6/30/2018	3	-8	-6	-6	N/A
3/31/2018	3	-8	N/A	-6	N/A
12/31/2017	3	-8	N/A	-6	N/A
9/30/2017	3	-8	N/A	-6	N/A
6/30/2017	3	-8	N/A	-6	N/A
3/31/2017	4	-8	N/A	-3	N/A
12/31/2016	4	-9	N/A	-1	N/A
9/30/2016	4	-8	N/A	-4	N/A
6/30/2016	5	-8	N/A	-7	N/A
3/31/2016	5	-8	N/A	-9	N/A
12/31/2015	6	-7	N/A	-10	N/A
9/30/2015	6	-7	N/A	-10	N/A
6/30/2015	6	-6	N/A	-11	N/A
3/31/2015	8	-6	N/A	-13	N/A
12/31/2014	10	-7	N/A	-15	N/A
9/30/2014	9	-10	N/A	-14	N/A
6/30/2014	8	-13	N/A	-14	N/A
3/31/2014	6	-12	N/A	-12	N/A
12/31/2013	4	-11	N/A	-11	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che PBN rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che PBN rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che PBN rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di PBN ( 25% all'anno) crescerà più rapidamente del mercato German ( 5.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di PBN ( 25% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di PBN è previsto essere elevato tra 3 anni

Alterity Therapeutics Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Alterity Therapeutics Limited, Annual General Meeting, Nov 22, 2024

Alterity Therapeutics Limited Announces Chief Financial Officer Changes

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.406192 million.

Alterity Therapeutics Limited Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $6 million.

Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.8 million.

Alterity Therapeutics Limited Announces CFO Changes

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

New minor risk - Shareholder dilution

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.8 million.

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy

New major risk - Market cap size

Alterity Therapeutics Limited, Annual General Meeting, Nov 29, 2023

New minor risk - Financial data availability

Alterity Therapeutics Limited Grants New Composition of Matter Patent in Europe for Neurodegenerative Diseases Including Parkinson's and Alzheimer's

Alterity Therapeutics Limited Announces an Independent Data Monitoring Committee Recommends the ATH434-201 Phase 2 Study

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

Alterity Therapeutics Enrolls First Patient in Australia in Ath434 Global Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Limited Receives Regulatory Approval for Phase II Trial in France and Austria

Alterity Therapeutics Limited Announces A Study Recently Published in the Journal Neurotherapeutics Demonstrated Its Lead Clinical Asset, Ath34, Was Neuroprotective in A Genetic Model of Parkinson's Disease

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy

Alterity Therapeutics Limited Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy

Alterity Therapeutics Limited Announces A New Composition of Matter Patent Allowed by the United States Patent and Trademark Office

Insufficient new directors

Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting

Alterity Therapeutics Limited, Annual General Meeting, Nov 11, 2022

Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the Biomuse Natural History Study At the International Congress of Parkinson's Disease and Movement Disorders

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe

Alterity Therapeutics Limited Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Limited Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy

Alterity Therapeutics Limited Launches ATH434 Phase 2 Clinical Trial

Insufficient new directors

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom

Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting

Alterity Therapeutics Announces Publication Demonstrating ATH434 Is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson’s Disease

Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson’S and Alzheimer’S

Alterity Therapeutics Limited Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial

Alterity Therapeutics Announces Data Was Presented from the Company’s Biomarkers of Progression in Multiple System Atrophy Study

United States Patent and Trademark Office Issues Notice of Allowance for Patent Application of Alterity Therapeutics to Expand its Portfolio of Compounds for Neurodegenerative Diseases Including Alzheimer's and Parkinson's

Alterity Therapeutics Limited Announces New Publication Demonstrates ATH434 Is Neuroprotective

Alterity Therapeutics Limited announced that it has received AUD 17.17604 million in funding

Alterity Therapeutics Granted Anew Us Patent Targeting Major Neurodegenerative Diseases Including Alzheimer's and Parkinson's

Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial

Alterity Therapeutics Limited to Report First Half, 2021 Results on Feb 25, 2021

Alterity Therapeutics Limited Appoints Dr. David Stamler as CEO

Alterity Announces Approval of US Patent for Next Generation Compounds to Treat Neurodegenerative Diseases

Alterity Therapeutics Commences Enrolling Multiple System Atrophy Patients in bioMUSE Study

Alterity Therapeutics Limited announced that it expects to receive AUD 35 million in funding

Alterity Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Alterity Therapeutics Limited to Report Fiscal Year 2020 Results on Sep 09, 2020

Full year earnings released - €0.011 loss per share

Full year earnings released - €0.011 loss per share

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita